Regulator warns of small risk of serious condition in people having RSV jab
It can affect people's senses, movement, breathing and heartbeat – usually starting in the arms and legs before spreading to other areas.
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug alert for the Abrysvo (made by Pfizer) and Arexvy (GSK) vaccines for RSV after they were linked to 21 suspected cases of Guillain-Barre syndrome in adults aged 60 and over.
However, the Commission on Human Medicines still advises that 'the benefits of vaccination against RSV outweigh the small risk of developing Guillain-Barre syndrome in older adults'.
In its alert, the MHRA said: 'Healthcare professionals should advise all recipients of Abrysvo and Arexvy that they should be alert to signs and symptoms of Guillain-Barre syndrome and, if they occur, to seek immediate medical attention as it requires urgent treatment in hospital.'
It warned staff to be alert to the signs and symptoms of the syndrome.
It added that there is currently no evidence of an increased risk of Guillain-Barre syndrome in pregnant women following vaccination with Abrysvo, the only RSV vaccine approved for use during pregnancy.
The RSV vaccine helps protect against respiratory syncytial virus, which can make older adults and babies seriously ill.
RSV can cause bronchiolitis in babies which can cause breathing problems, while it can cause pneumonia in older people, both of which may require hospital stays.
The Pfizer RSV vaccine Abrysvo is currently offered on the NHS to adults aged 75 to 79 and to pregnant women.
The GSK RSV vaccine Arexvy is not currently available on the NHS but may be available privately in the UK.
Symptoms of Guillain-Barre syndrome can include tingling, numbness or pins and needles in feet and hands, muscle weakness and difficulty moving joints.
There may also be problems breathing and drooping face muscles or trouble swallowing or speaking.
Up to June 2, the MHRA has received 21 Yellow Card reports of suspected Guillain-Barre syndrome in older adults (aged 75-79 where known) following Abrysvo.
This is in the context of over 1.9 million doses of Abrysvo administered, it said.
Over the same time period, the MHRA has not received any Yellow Card reports of suspected Guillain-Barre syndrome following Arexvy, however there has been very limited use of this vaccine in the UK to date.
In the US, one study suggested Abrysvo and Arexvy were associated with nine and seven excess Guillain-Barre syndrome cases per million vaccine doses administered, respectively.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Record
16 hours ago
- Daily Record
Pfizer Covid-19 vaccine linked to eye problems that could damage vision in new study
Researchers looked at how the vaccine affected patients' corneas - the clear front part of the eye that allows light to come in Scientists have found that Pfizer's COVID-19 vaccine may increase the risk of serious eye damage, potentially leading to loss of sight, according to a recent study. The new research conducted by Turkish scientists specifically examined how the jab affected patients' corneas - the transparent front part of the eye that lets light in. In 64 subjects, changes in the inner layer of the cornea, known as the endothelium, were measured before receiving the first Pfizer dose and two months after the second. The results indicated that having two doses of the vaccine led to thicker corneas, fewer endothelial cells in the eye, and more variation in the size of these specialised cells that form the endothelium. In the short term, these alterations suggest the Pfizer vaccine might temporarily weaken the endothelium, even though patients didn't experience noticeable vision problems during the study. For individuals with healthy eyes, these minor changes likely won't impact vision immediately. However, scientists stated that if these changes persist for years, they could result in corneal swelling or blurred vision, particularly in those with pre-existing eye conditions or individuals who have undergone a corneal transplant. A thicker cornea and reduced cell density may contribute to eye conditions like corneal oedema, bullous keratopathy, or corneal decompensation, which can all lead to permanent vision loss in severe cases, especially if left untreated, reports the Express. The researchers cautioned in the study, published Wednesday (July 16) in the journal Ophthalmic Epidemiology: "The endothelium should be closely monitored in those with a low endothelial count or who have had a corneal graft." Nevertheless, the team did not advise against the Pfizer jab and will still require long-term studies on additional patients' vision to determine if these alterations persist months and years following the injections. A representative from Pfizer UK stated they regarded the findings "very seriously". In a statement to the Express, they said: "Patient safety is paramount and we take any reports of adverse events very seriously. Adverse event reports do not imply causality, and in the context of vaccination such events may be unrelated to administration of the vaccine. "Hundreds of millions of doses of the Pfizer-BioNTech COVID-19 vaccine have been administered globally and the benefit-risk profile of the vaccine remains positive for all authorised indications and age groups. "As with every medicine and vaccine, including the Pfizer-BioNTech COVID-19 vaccine, Pfizer has robust processes to meet its regulatory responsibilities to closely monitor, report and analyse all adverse events, and collect relevant information to assess any new potential safety risks that may be associated with the COVID-19 vaccine." Pfizer said as well as their pharmacovigilance efforts and compliance with regulatory requirements related to quality and safety, they also work with regulatory authorities to independently monitor the safety profile of the vaccine. Join the Daily Record WhatsApp community! Get the latest news sent straight to your messages by joining our WhatsApp community today. You'll receive daily updates on breaking news as well as the top headlines across Scotland. No one will be able to see who is signed up and no one can send messages except the Daily Record team. All you have to do is click here if you're on mobile, select 'Join Community' and you're in! If you're on a desktop, simply scan the QR code above with your phone and click 'Join Community'. We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don't like our community, you can check out any time you like. To leave our community click on the name at the top of your screen and choose 'exit group'. If you're curious, you can read our Privacy Notice. In any case, patients who receive the COVID-19 vaccine "should talk to their doctor, pharmacist or nurse if they have any concerns or experience any side effects" - including any possible side effects not listed in the package leaflet. "As with all medicines and vaccines... Pfizer has stringent procedures in place to fulfil its regulatory obligations to closely monitor, report, and analyse all adverse events, as well as gather pertinent information to evaluate any new potential safety risks that may be associated with the COVID-19 vaccine," the spokesperson added.
Times
a day ago
- Times
Weight-loss jabs linked to five deaths in Scotland
Weight-loss injections have been linked to the deaths of five people in Scotland, while hundreds more report having become ill after using them. The jabs were developed to suppress appetite among obese patients with type 2 diabetes but have become more commonly used as a quick-fix diet aid. Last year a Scottish nurse, Susan McGowan, was the first person in the UK whose death was directly linked to the prescription-only medication. Now, however, the Medicines and Healthcare Regulatory Agency (MHRA) has said it has received five reports of fatalities linked to weight-loss jabs north of the border. The watchdog said in March that it had been notified 361 times since January last year of patients in Scotland who have suffered illness after taking the drugs.
Daily Mail
2 days ago
- Daily Mail
EXCLUSIVE REVEALED: Weight loss injections now linked to FIVE deaths in Scotland
Fat jabs have been linked to the deaths of five people in Scotland, including one reported to watchdogs this year. The prescription-only drugs, originally developed to suppress appetite among obese patients with type 2 diabetes, have become popular as a quick fix for people looking to lose weight. However, health watchdogs have received hundreds of reports from people who have become ill after taking them. In March, the Medicines and Healthcare Regulatory Agency (MHRA) disclosed it had been notified 361 times since January last year of patients in Scotland who have suffered illness after taking the drugs. MailOnline recently reported that 12 Scots were taken to A&E between April 2023 and August 2024 with complications from weight loss injections in the same health board area where Britain's first fat jab victim died. Now, the watchdog has revealed details of the most serious cases linked to the drugs in Scotland, stating it has received five reports of fatalities. Three reports concerned patients using the medications for weight loss alone while a fourth patient had prescriptions to treat diabetes. Details of the fifth reported fatality were not provided. Nurse Susan McGowan became the first person in the UK whose death was directly linked to a weight-loss jab. She died at Monklands Hospital in Airdrie last September. The 58-year-old suffered organ failure, septic shock and pancreatitis after taking two jabs of 'prescribed tirzepatide', sold under the brand name Mounjaro. Dr Samantha Robson, a GP working in weight management, said it is important not to draw conclusions on the deaths without clear clinical context. She said the drugs can be 'transformational medications when used correctly, for the right patients, with the right support', but added that there are instances of people taking them improperly. She said: 'Many patients are accessing these medications privately—through clinics, prescribers, and worryingly, through unregulated online pharmacies and social media.' Dr Robson is the medical director of Temple Clinic in Aberdeen, which prescribes GLP-1 medications 'under strict medical supervision and with intensive support'. However, she said it is alarmingly easy for people to obtain them without proper assessment, supervision or education. 'I am aware of cases where patients with a history of eating disorders, including anorexia nervosa, are lying about their weight and health to access these drugs purely to suppress appetite and further restrict their intake. This is deeply dangerous. 'There are also growing reports of counterfeit medications being sold online—products that may be contaminated, contain no active ingredient, or in some cases may be resold used pens from patients who stopped the medication but are hoping to recoup some cost.' She added: 'These medications are not inherently dangerous — but unsupervised, unregulated use absolutely is. And if we continue to allow them to be used like crash diets in injectable form, the current headlines will be the tip of the iceberg. This is not just a public health issue — it's an ethical one.' MailOnline has previously revealed that black market seizures in Scotland of potentially dangerous weight loss drugs have soared. The MHRA is investigating whether a genetic trait puts some patients at greater risk of side effects. Dr Alison Cave, its chief safety officer, said: 'Patient safety is our top priority and no medicine would be approved unless it met our expected standards of safety, quality and effectiveness. 'On the basis of the current evidence, the benefits of GLP-1 medicines outweigh the potential risks when used for the licensed indications. The decision to start, continue or stop treatments should be made jointly by patients and their doctor, based on full consideration of the benefits and risks.'
